Clexane Dose for DVT Prophylaxis in CKD with eGFR 21
For a patient with an eGFR of 21 mL/min (severe renal impairment), use enoxaparin 30 mg subcutaneously once daily for DVT prophylaxis. This is the manufacturer-recommended dose reduction for patients with creatinine clearance <30 mL/min 1.
Rationale for Dose Reduction
The evidence strongly supports dose adjustment in severe renal impairment due to:
- Reduced renal clearance: Enoxaparin clearance is reduced by 44% in patients with severe renal impairment (CrCl <30 mL/min) 1
- Bleeding risk: Meta-analyses demonstrate a 2- to 3-fold increased risk of major bleeding when standard unadjusted doses are used in severe renal insufficiency 1
- Drug accumulation: Unlike some other LMWHs, enoxaparin accumulates significantly in renal impairment 1
Dosing Algorithm by Renal Function
For prophylaxis:
- CrCl ≥30 mL/min: Standard dose 40 mg SC once daily
- CrCl <30 mL/min (including your patient with eGFR 21): Reduced dose 30 mg SC once daily 1, 2
For treatment doses (if needed): 1 mg/kg SC once every 24 hours (instead of twice daily) in severe renal impairment 1, 2
Important Caveats
Monitoring considerations:
- While routine anti-Xa monitoring is generally not recommended 3, consider it in this borderline severe renal impairment if:
- Bleeding occurs
- Prolonged therapy is needed
- Patient has additional bleeding risk factors
Alternative considerations:
- Some evidence suggests caution even with CrCl 30-50 mL/min, with renal clearance reduced by 31% in moderate impairment 1
- Unfractionated heparin (UFH) may be considered as an alternative in severe renal impairment, as it has minimal renal clearance 1, 3
- Dalteparin 5000 IU daily showed no bioaccumulation in studies of patients with CrCl <30 mL/min 1, though it lacks specific manufacturer dosing recommendations for renal impairment
Clinical Monitoring
Monitor for:
- Bleeding complications (most critical outcome affecting mortality)
- Hemoglobin levels serially
- Renal function - if it worsens further, reassess anticoagulation strategy
- Consider switching to UFH if eGFR drops below 15-20 mL/min or if bleeding occurs
The 30 mg daily dose represents the only LMWH with specific manufacturer guidance and regulatory approval for dose adjustment in severe renal impairment 1, making it the evidence-based choice for your patient.